NEW YORK, Nov. 21, 2017 /PRNewswire/ --
If you want a Stock Review on BCRX, CELG, EXEL, or GERN then come over to
Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc.'s shares declined 0.22%, finishing last Friday's session at $4.51. A total volume of 449,547 shares was traded. Over the previous three months, the stock has advanced 2.97%. The Company's shares are trading below their 50-day moving average by 9.14%. Additionally, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have a Relative Strength Index (RSI) of 40.03.
On November 16th, 2017, BioCryst Pharma announced that its executives are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017 at 3:00 p.m. ET in New York. A live audio webcast and replay of the presentation may be accessed under the Events page of the Company's website. Your complete research report on BCRX can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=BCRX
On Friday, shares in Summit, New Jersey headquartered Celgene Corp. ended the session 0.91% lower at $103.15. The stock recorded a trading volume of 6.12 million shares. The Company's shares are trading below their 200-day moving average by 18.18%. Moreover, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have an RSI of 34.72.
On October 27th, 2017, research firm Morgan Stanley upgraded the Company's stock rating from 'Underweight' to 'Equal-Weight'.
On November 16th, 2017, Celgene and bluebird bio, Inc. announced that bb2121, a chimeric antigen receptor T-cell therapy targeting b-cell maturation antigen in previously treated patients with multiple myeloma, has been granted Breakthrough Therapy Designation (BTD) by the US FDA and PRIority MEdicines eligibility by the European Medicines Agency. BTD designation and PRIME eligibility for bb2121 were based on preliminary clinical data from the ongoing phase 1 study CRB-401. A free report on CELG is just a click away at: http://dailystocktracker.com/registration/?symbol=CELG
South San Francisco, California headquartered Exelixis Inc.'s stock dropped 2.77%, to close the day at $25.65 with a total trading volume of 1.76 million shares. The Company's shares have surged 72.03% since the start of this year. The stock is trading 7.53% above its 200-day moving average. Additionally, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have an RSI of 49.12. Sign up for your complimentary research report on EXEL at: http://dailystocktracker.com/registration/?symbol=EXEL
Shares in Menlo Park, California-based Geron Corp. recorded a trading volume of 1.03 million shares. The stock ended at $1.90, down 1.04% from the last trading session. The Company's shares are trading below their 50-day moving average by 10.21%. Furthermore, shares of Geron, which operates as a biopharmaceutical company, have an RSI of 40.29.
On November 07th, 2017, Geron announced that John A. Scarlett, M.D., President and Chief CEO, is scheduled to present at the Piper Jaffray 29th Annual Healthcare Conference on November 28th, 2017, at 3:30 p.m. ET in New York. A live audio webcast of the presentation will be available under the Investors section of the Company's website. Register for free on DailyStockTracker.com and download the latest research report on GERN at: http://dailystocktracker.com/registration/?symbol=GERN
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. RohitTuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected]Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/biotech-stock-performance-review----biocryst-pharma-celgene-exelixis-and-geron-300560053.html
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All